US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

10.91

-0.2500-2.24%

Post-market: 10.85-0.0600-0.55%17:23 EDT

Volume:223.69K

Turnover:2.50M

Market Cap:588.97M

PE:-1.74

High:11.50

Open:11.08

Low:10.82

Close:11.16

52wk High:17.40

52wk Low:7.90

Shares:53.98M

Float Shares:17.65M

Volume Ratio:0.55

T/O Rate:1.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.2610

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:1.07

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026

Eikon to present six abstracts at ASCO annual meeting

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics price target lowered to $5 from $7 at Wedbush

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EIKN"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":10.91,"timestamp":1779480000000,"preClose":11.16,"halted":0,"volume":223685,"hourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.91,"latestTime":"17:23 EDT","volume":20859,"amount":235365.89,"timestamp":1779485023477,"change":-0.06,"changeRate":-0.0055,"amplitude":0.082493},"delay":0,"changeRate":-0.022401433691756272,"floatShares":17648000,"shares":53984300,"eps":-6.261028,"marketStatus":"Closed Memorial Day","change":-0.25,"latestTime":"05-22 16:00:00 EDT","open":11.08,"high":11.5,"low":10.8248,"amount":2497767,"amplitude":0.060502,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.261028,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":11.16,"preHourTrading":{"tag":"盘前","latestPrice":10.82,"preClose":11.16,"latestTime":"04:01 EDT","volume":1,"amount":10.82,"timestamp":1779436861734,"change":-0.34,"changeRate":-0.030466,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.91,"latestTime":"17:23 EDT","volume":20859,"amount":235365.89,"timestamp":1779485023477,"change":-0.06,"changeRate":-0.0055,"amplitude":0.082493},"volumeRatio":0.5483502795797158},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.5483502795797158,"shares":53984300,"dividePrice":0,"high":11.5,"amplitude":0.060502,"preClose":11.16,"low":10.8248,"week52Low":7.9,"pbRate":"1.07","week52High":17.4,"institutionHeld":0,"latestPrice":10.91,"eps":-6.261028,"divideRate":0,"volume":223685,"delay":0,"ttmEps":-6.261028,"open":11.08,"prevYearClose":18,"prevWeekClose":10.91,"prevMonthClose":9.615,"prevQuarterClose":10.58,"fiveDayClose":13.25,"twentyDayClose":9.655,"sixtyDayClose":13.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-05-22","current":-1.742525,"percent":0.648649,"low":-3.139466,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"high":-1.429233,"avg":-2.047009,"sd":0.418194,"marketCap":604186273},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273}],"updateTime":1779698983554},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637368971","title":"Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368971?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:19","pubTimestamp":1779405560,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics on May 21, 2026 flagged six oncology abstracts that will be presented at the 2026 ASCO annual meeting starting May 29, 2026.Planned presentations highlight ongoing mid- to late-stage studies of EIK1001 in first-line stage 4 non-small cell lung cancer, including combinations with standard regimens, with an update focused on efficacy, safety, and immune-response profiling.Additional abstracts will outline early clinical progress for EIK1003 in advanced solid tumors, including combination use with paclitaxel, alongside updated monotherapy findings.EIK1005 updates will cover first-in-human safety and pharmacokinetics in healthy participants, with a separate trial design for use alone or with pembrolizumab in advanced solid tumors such as MSI-H or dMMR cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL2RsHWf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357662","title":"Eikon to present six abstracts at ASCO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357662?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:12","pubTimestamp":1779397923,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics will present six oncology abstracts at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago starting May 29, 2026.Data presentations will cover EIK1001 in first-line stage 4 non-small cell lung cancer, including combination regimens with pembrolizumab.Additional updates will include EIK1003 results in advanced solid tumors, including combination work with paclitaxel, alongside early clinical progress for WRN inhibitor candidate EIK1005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1lZ1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357327","title":"Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357327","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357327?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:05","pubTimestamp":1779397500,"startTime":"0","endTime":"0","summary":"Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299796/0/en/Eikon-Therapeutics-Announces-Availability-of-Six-Abstracts-for-Presentation-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","AFG","BK4117","BK4139","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246421","title":"Eikon Therapeutics price target lowered to $5 from $7 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246421","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246421?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:33","pubTimestamp":1778603632,"startTime":"0","endTime":"0","summary":"Wedbush lowered the firm’s price target on Eikon Therapeutics (EIKN) to $5 from $7 and keeps an Underperform rating on the shares after the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EIKN\",params:#limit:6,delay:false,,,undefined,":[]}}